A clinical case report of cystic fibrosis and liver cirrhosis in a child

Authors

  • V. A. Klymenko Kharkiv National Medical University, Ukraine,
  • O. V. Piontkovska Kharkiv Regional Clinical Children’s Hospital No. 1, Ukraine,
  • O. V. Pasichnyk Kharkiv Regional Clinical Children’s Hospital No. 1, Ukraine,
  • N. M. Drobova Kharkiv National Medical University, Ukraine,
  • K. O. Yanovska Kharkiv National Medical University, Ukraine,
  • S. I. Bevz Kharkiv Regional Clinical Children’s Hospital No. 1, Ukraine,
  • N. T. Sindieieva Kharkiv Regional Clinical Children’s Hospital No. 1, Ukraine,

DOI:

https://doi.org/10.14739/2310-1210.2018.5.141713

Keywords:

children, cystic fibrosis liver, cirrhosis

Abstract

Purpose. To analyze the history of a child with cystic fibrosis (CF) and liver cirrhosis.

Results of research. This clinical case report demonstrates the course of CF in a patient with a severe CFTR mutation delF508. The disease had severe course, mostly due to hepato-renal disorders.

From birth the child had a poor appetite, insufficient weight gain. A cough bothered the child from age of three months, and then pneumonia was diagnosed with a protracted course. CF was diagnosed by positive sweat chloride test (85/107 mmol/L) and clinical manifestations at the age of eight months.

CFTR mutation delF508 was found during genetic testing. The patient had chronic airways colonization with S. aureus and P. aeruginosa. At 1 year of age the child was infected by S. aureus, at 6 year of age – P. aeruginosa. The child received pathogenetic treatment including inhaled antibiotic therapy (tobramycin, colistin). The child constantly received the replacement enzyme therapy, hepatoprotective drugs and multivitamins. Antibiotic therapy was prescribed only for bronchopulmonary exacerbation.

At 8 years of age the biliary cirrhosis, portal hypertension and splenomegaly (+ 6.0 cm) were found. Type 1 diabetes mellitus was diagnosed at 9 years of age. The child's condition worsened progressively mostly due to hepato-renal disorders. The child needed permanent hospital care.

The last patient’s hospitalization lasted for 85 bed-days, including 52 days in the Department of Anesthesiology and Intensive Care because of the condition worsening due to multiple organ dysfunction syndrome that caused death at 17 years of age.

Conclusions. This clinical case report demonstrates the course and outcomes of cystic fibrosis with severe CFTR mutation delF508 and cirrhosis.

 

References

Kapranov, N. I., & Kashirskaya, N. Yu. (2014). Mukoviscidoz [Cystic fibrosis]. Moscow: Medpraktika. [in Russian].

Manovitskaya, N. V., Borodina, G. L., & Voytko, T. A. (2013). Dinamika klinicheskogo statusa vzroslykh pacientov s mukoviscidozom v respublike Belarus' [Dynamics of clinical status of adult patients with mucoviscidosis in the Republic of Belarus]. Problemy zdorov'ya i e'kologii, 2(36), 29–34. [in Russian].

Самойленко, В. А., Бабаджанова, Г. Ю., Нагорный, А. Б., & Красовский, С. А. (2013). Mukoviscidoz i sakharnyj diabet [Cystic fibrosis and diabetes]. Atmosfera. Pul'monologiya i allergologiya, 2, 32–37. [in Russian].

Kashirskaya, N. Yu., Kapranov, N. I., Kusova, Z. A., & Shelepneva, Z. A. (2010). Porazhenie podzheludochnoj zhelezy pri mukoviscidoze [The defeat of the pancreas in cystic fibrosis]. E'ksperemental'naya i klinicheskaya gastroe'nterologiya, 8, 98–103. [in Russian].

Rohovyk, N. V. (2013). Metabolizm vitaminu E pry mukovistsydozi [The metabolism of vitamin E in cystic fibrosis]. Pediatriia, akusherstvo ta hinekolohiia, 76(3), 25–30. [in Ukrainian].

Burgel, P. R., & Bellis, G. (2015). Accuracy of modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry. Journal of Cystic Fibrosis, 14, 33. doi: 10.1016/S1569-1993(15)30105-3.

Debray, D., Kelly, D., Houwen, R., Strandvik, B., & Colombo, C. (2011). Best practice guidance for2 the diagnosis and management of cystic fibrosis-associated liver disease. Journal of Cystic Fibrosis, 10(2), S29–36. doi: 10.1016/S1569-1993(11)60006-4.

Flass, T., & Narkewicz, M. R. (2013). Cirrhosis and other liver disease in cystic fibrosis. Journal of Cystic Fibrosis, 12(2), 116–124. doi: 10.1016/j.jcf.2012.11.010.

Ebdon, A. M., Nolan, S., Dick, K., Alexander, S., Bridges, N., & Carr, S. B. (2014). Continuous glucose monitoring is a useful tool for diagnosis of cystic fibrosis related diabetes. Journal of Cystic Fibrosis, 13(2), S13. doi: https://doi.org/10.1016/S1569-1993(14)60042-4.

Ali, B. R. (2009). Is cystic fibrosis-related diabetes an apoptotic consequence of ER stress in pancreatic cells? Med. Hypotheses, 72(1), 55–57. doi: 10.1016/j.mehy.2008.07.058.

Minicucci, L. (2012). New diagnostic and therapeutic approaches in cystic fibrosis related diabetes (CFRD). Journal of Cystic Fibrosis, 7(6), 67–73.

Flume, P. A., Mogayzel, P. J., Robinson, K. A., Goss, C. H., Rosenblat, R. L., Kuhn, R. J., et al. (2009). Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. American journal of respiratory and critical care medicine, 180(9), 802–808. doi: 10.1164/rccm.200812-1845PP.

Schmid, K., Fink, K., Holl, R. W., Hebestreit, H., & Ballmann, M. (2013). Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis, 13(1), 80–85. doi: 10.1016/j.jcf.2013.06.001.

Burgess, J. C., Bridges, N. Y., & Simmonds, N. J. (2012). 1. Using HbAlc and random blood glucose to screen for cystic fibrosis related diabetes (CFRD). Journal of Cystic Fibrosis, 11(116), 56.

Downloads

How to Cite

1.
Klymenko VA, Piontkovska OV, Pasichnyk OV, Drobova NM, Yanovska KO, Bevz SI, Sindieieva NT. A clinical case report of cystic fibrosis and liver cirrhosis in a child. Zaporozhye Medical Journal [Internet]. 2018Sep.24 [cited 2024Nov.5];(5). Available from: http://zmj.zsmu.edu.ua/article/view/141713

Issue

No. 5 (2018)

Section

Case Reports

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)